bit.bio raises in extra of $100 million in first shut of Sequence B financing

Right now bit.bio pronounces the primary shut of their Sequence B financing of $103 million.

New and present institutional and strategic traders within the Sequence B spherical, to this point, embrace Arch Ventures, Charles River Laboratories, Foresite Capital, Nationwide Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.

The funding will speed up the medical growth of the corporate’s proprietary cell coding expertise opti-ox – a breakthrough gene engineering method that allows limitless batches of any human cell to be manufactured constantly at scale by way of direct reprogramming of stem cells.

It’ll additionally help the continued progress of the corporate’s ioCells product portfolio – the place opti-ox is used to create human cell merchandise which can be distinctive as a result of they provide consistency at scale and the cells are extremely outlined. Entry to ioCells permits our companions and clients to conduct translational analysis and drug growth with physiologically related human cell fashions. Utilizing human cells to bridge the interpretation hole in drug growth will enhance possibilities of medical success and the potential to unlock a brand new technology of medicines.

bit.bio has already launched two merchandise for analysis and drug discovery – glutamatergic neurons and skeletal myocytes – with illness fashions and different cell sorts to comply with.

I’m thrilled that bit.bio is supported by world class traders and strategic companions. The capital will allow us to speed up our medical and industrial scale-up and to ship cell therapies for each affected person, in every single place.”


Mark Kotter, CEO and Founder, bit.bio

#bitbio #raises #extra #million #shut #Sequence #financing